NCT05409261View on ClinicalTrials.gov

Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

September 25, 2022

Study Completion Date

March 31, 2025

Conditions
COVID-19Vaccine ReactionSARS CoV 2 InfectionVaccine Adverse Reaction
Interventions
BIOLOGICAL

Ad26.COV2.S

Recombinant vaccine, contains Adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein

Trial Locations (1)

251

CVD-MALI, Bamako

All Listed Sponsors
collaborator

CEPI

OTHER

collaborator

Innovative clinical research network in vaccinology (IREIVAC)

UNKNOWN

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

APHP

OTHER

collaborator

Center for Vaccine Development - Mali

OTHER

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT05409261 - Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine | Biotech Hunter | Biotech Hunter